FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Gerngross Tillman U.
(Last) (First) (Middle)
C/O ADAGIO THERAPEUTICS, INC.
303 WYMAN STREET, SUITE 300
(Street)
WALTHAM MA 02451
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
08/05/2021 		3. Issuer Name and Ticker or Trading Symbol
Adagio Therapeutics, Inc. [ ADGI ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 1,985,295
I
By LLC (1)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock   (2)   (2) Common Stock 25,000,000 (2) I By LLC (1)
Series B Preferred Stock   (2)   (2) Common Stock 220,380 (2) I By LLC (1)
Series C Preferred Stock   (2)   (2) Common Stock 640,320 (2) I By LLC (1)
Stock Option (Right to Buy)   (3) 05/06/2031 Common Stock 3,419,345 10.14 D  
Stock Option (Right to Buy)   (4) 07/03/2031 Common Stock 962,825 12.8 D  
Explanation of Responses:
1. These shares are held by Adimab, LLC (the "LLC"). The Reporting Person is an officer and member of the Board of Directors of the LLC and, as such, may be deemed to have shared voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
2. Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into 5 shares of Common Stock, has no expiration date and is expected to automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
3. One quarter (1/4) of the options shall vest on May 7, 2022, and thereafter, the remainder of the options shall vest in 36 equal monthly installments on the 7th day of each month, subject to the Reporting Person's continuous service on each vesting date.
4. One quarter (1/4) of the options shall vest on July 4, 2022, and thereafter, the remainder of the options shall vest in 36 equal monthly installments on the 4th day of each month, subject to the Reporting Person's continuous service on each vesting date.
/s/ Dorothy Vinsky, Attorney-in-Fact 08/05/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5)

       Know all by these presents, that the undersigned hereby 
constitutes and appoints Jane Pritchett Henderson of Adagio Therapeutics, Inc.
(the "Company") and Divakar Gupta, Courtney Tygesson, Ryan Sansom, 
Erika Kaneko, David Brinton, Barry Kuang, Sarah Howard and Dorothy Vinsky of
Cooley LLP, signing individually, the undersigned's true and lawful attorneys-in
fact and agents to:

        (l)	Prepare, execute in the undersigned's name and on 
the undersigned's behalf, and submit to the Securities and 
Exchange Commission (the "SEC"), a Form ID and Forms 3, 4 and 5 
(including amendments thereto and joint filing agreements in 
connection therewith) in accordance with Section 16 of the 
Securities Exchange Act of 1934, as amended (the "Exchange 
Act"), and the rules thereunder, in the undersigned's capacity 
as an officer, director or beneficial owner of more than 10% of a 
registered class of securities of the Company;

        (2)	Do and perform any and all acts for and on behalf 
of the undersigned that may be necessary or desirable to 
prepare and execute any such Form ID and Forms 3, 4 or 5 
(including amendments thereto and joint filing agreements in 
connection therewith) and file such forms with the SEC and any 
stock exchange, self-regulatory association or any similar 
authority; and

       (3)	Take any other action of any type whatsoever in 
connection with the foregoing that, in the opinion of such 
attorney-in-fact, may be of benefit to, in the best interest 
of, or legally required of the undersigned, it being 
understood that the documents executed by the attorney-in-fact 
on behalf of the undersigned pursuant to this Power of 
Attorney shall be in such form and shall contain such terms 
and conditions as the attorney-in-fact may approve in the 
attorney-in-fact's discretion.

       The undersigned hereby grants to each such attorney-in- 
fact full power and authority to do and perform any and every 
act and thing whatsoever requisite, necessary, or proper to be 
done in the exercise of any of the rights and powers herein 
granted, as fully to all intents and purposes as the 
undersigned might or could do if personally present, with full 
power of substitution or revocation, hereby ratifying and 
confirming all that such attorney-in-fact , or such attorney-in- 
fact's substitute or substitutes, shall lawfully do or cause to 
be done by virtue of this power of attorney and the rights and 
powers herein granted. The undersigned acknowledges that the 
foregoing attorneys-in-fact, and their substitutes, in serving 
in such capacity at the request of the undersigned, are not 
assuming (nor is the Company assuming) any of the undersigned's 
responsibilities to comply with Section 16 of the Exchange Act.

       This Power of Attorney shall remain in full force and 
effect until the earliest to occur of (a) the undersigned is 
no longer required to file Forms 3, 4 and 5 with respect to 
the undersigned's holdings of and transactions in securities 
issued by the Company, (b) revocation by the undersigned  in a 
signed writing delivered to the Company and the foregoing 
attorneys-in fact or (c) as to any attorney-in-fact 
individually, until such attorney-in-fact is no longer 
employed by the Company or employed by or a partner at Cooley 
LLP or another law firm representing the Company, as 
applicable.
       
       IN WTINESS WHEREOF, the undersigned has caused this 
Power of Attorney to be signed as of the date written below.

Date: July 13, 2021			/s/ Tillman U. Gerngross
						Tillman U. Gerngross, Ph.D.